Eisai Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effects of Donepezil Hydrochloride (E2020) in the Management of Patients with Alzheimer’s Disease in a Nursing Home Facility

E2020-A001-311

Study Overview

E2020
donepezil
Not available
Sep 1996 - Apr 1998
Alzheimer's disease
The primary efficacy endpoint was to evaluate the efficacy (primary efficacy parameter NPI-NH 10 item) of donepezil HCI E2020, versus Placebo, in the management of Alzheimer's disease patients in a nursing home facility.

  • Males and females (age 50 years and over)

  • Completed

  • Phase 3

  • United States

Results

CSR Synopsis

Download PDF

Lay Summary

No download available

Publication reference citation

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A randomized, double-blind, placebocontrolled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc. 2001;49:1590-9.

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Protocol
SAP
Sample CRF
Full CSR